Following EMT, trastuzumab resistant PTEN deficient breast cancer cells transform HER2+ cells to a more aggressive TNBC phenotype with reduction in HER2, estrogen, and progesterone receptor expression while increasing proliferation. Here, ERBB2 is linked to breast cancer.